Current Translational Scholars
Eric BensonIndiana University School of Medicine
Kelly A. BirdwellVanderbilt University
Vidya ChidambaranCincinnati Children’s Hospital Medical Center
Julio D. DuarteUniversity of Illinois at Chicago
Jerry IngrandeStanford University
Vivian KawaiVanderbilt University Medical Center
Joseph P. KitzmillerOhio State University
Sulggi A. LeeUniversity of California, San Francisco
Joshua P. LewisUniversity of Maryland
Tracy L. McGregorVanderbilt University
Andrew A. MonteUniversity of Colorado School of Medicine
Peter H. O'DonnellUniversity of Chicago
Stuart A. Scott, Ph.D.Icahn School of Medicine at Mount Sinai
Manish R. Sharma, M.D.University of Chicago
Sophie Sokolow, MPharm, R.Ph, Ph.D.University of California, Los Angeles
Note: This is an archived page that is not updated.
The Translational Scholar Career Awards in Pharmacogenomics and Personalized Medicine program will not continue in the foreseeable future. For potential future career awardees whose work falls into NIGMS’ interest area, you will often be able to apply for the regular K23 awards under the clinical pharmacology topic area. For others, please look into your relevant categorical institutes who participate in the NIH K23 program or NIH K08 program. For more information, see K23 program staff contacts and K08 program staff contacts.
The Translational Scholar Career Awards in Pharmacogenomics and Personalized Medicine (K23) addressed the NIH-wide goal of expanding the pool of well-trained individuals who can lead the implementation of personalized medicine. The highly selective program aimed to cross-train leaders in both clinical research core competencies and modern methods required to conduct pharmacogenomics research in patient populations. The awards were designed to train leaders to understand and integrate clinical practice, genetics and genomics, pharmacology and drug science, statistics and epidemiology and/or clinical trial design.
To facilitate cross-training in basic and clinical research in personalized medicine, the Translational Scholar Career Award program leveraged the strengths of two large and successful NIH programs--the Clinical and Translational Science Award (CTSA) and the NIH Pharmacogenomics Research Network (PGRN). The Translational Scholar Career Award program was described in PA-11-009.
In addition to providing the foundation for the K23 program, a link between the CTSA program and the PGRN also fostered collaboration between basic researchers and clinically oriented ones, thereby propelling translational science.
Contact information for each participating NIH component is listed below.
National Cancer Institute (NCI)Susan Lim, Ph.D., Cancer Training Branch, Center for Cancer TrainingTel: 301-496-8580E-mail: email@example.com
National Institute on Drug Abuse (NIDA)Joni Rutter, Ph.D., Division of Basic Neuroscience and Behavioral ResearchTel: 301-435-0298E-mail: firstname.lastname@example.org
National Institute of General Medical Sciences (NIGMS)Rochelle M. Long, Ph.D., Division of Pharmacology, Physiology, and Biological ChemistryTel: 301-594-3827E-mail: email@example.com
National Institute of Nursing Research (NINR)David Banks, Ph.D., Office of Extramural ProgramsTel: 301-496-9558E-mail: firstname.lastname@example.org
National Center for Advancing Translational Sciences (NCATS)Heng Xie, M.D., M.P.H., Ph.D., Division of Clinical InnovationTel: 301-443-8063E-mail: XieHe@mail.nih.gov
Food and Drug Administration (FDA)--Center for Drug Evaluation and Research Although the FDA is not formally participating in this initiative, K23 awardees are encouraged to engage in scientific exchange with the FDA. Awardees may participate with FDA by serving as visiting lecturers, engaging in voluntary exploratory data submissions (VXDS) of their research and meeting with regulatory scientists in various FDA offices including the Office of Clinical Pharmacology, Office of Translational Sciences and others. Rotations at the FDA allow K23 awardees to learn more about therapeutic product research and oversight. It might also be possible for K23 awardees to undertake special projects associated with the FDA.Issam Zineh, Pharm.D., M.P.H., Office of Clinical PharmacologyTel: 301-796-4756E-mail: email@example.com
This page last reviewed on
1/3/2017 3:20 PM
Connect With Us: